Stockreport

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF 85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combina [Read more]